Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 4/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19144912 | 0.88 | IDO1 (0.64) | EPHX1IDO1SLC6A4FPR2PROKR1 | |
| SCHEMBL12066334 | 0.79 | IDO1 (0.68) | EPHX1IDO1SLC6A4FPR2PROKR1 | |
| SCHEMBL16979030 | 0.79 | SLC6A4 (0.49) | IDO1SLC6A4FPR2PROKR1SLC6A2 | |
| SCHEMBL11248115 | 0.77 | SLC6A4 (0.47) | IDO1SLC6A4FPR2PROKR1SLC6A2 | |
| SCHEMBL4598274 | 0.77 | SLC6A4 (0.47) | IDO1SLC6A4FPR2PROKR1SLC6A2 | |
| SCHEMBL744402 | 0.77 | SLC6A4 (0.47) | EPHX1IDO1SLC6A4FPR2PROKR1 | |
| SCHEMBL6373300 | 0.76 | SLC6A2 (0.56) | SLC6A4SLC6A2 | |
| SCHEMBL28601137 | 0.76 | FFAR1 (0.51) | FFAR1SLC6A4PTGS2SLC6A2CHRNB2 | |
| SCHEMBL16262381 | 0.76 | EPHX1 (0.41) | EPHX1IDO1SLC6A4FPR2PROKR1 | |
| Iodide SCHEMBL744206 | 0.76 | SLC6A4 (0.46) | EPHX1IDO1SLC6A4FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867650-B1 | HYDROXYMETHYLBORON COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7696347-B2 | Oxymethyl boron compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20080242859-A1 | Oxymethyl Boron Compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-02 | — | — | US | disclosed |
| EP-1867650-A1 | HYDROXYMETHYLBORON COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242859-A1 | Oxymethyl Boron Compounds | BPGM, DDT, DBN1 | EPHX1 1367/4885IDO1 468/4885FFAR1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.